ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals
Launched by CENTRE FOR ADDICTION AND MENTAL HEALTH · Apr 13, 2022
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial titled "ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals" is exploring a new approach to help women and non-binary individuals who struggle with methamphetamine use. The study focuses on using Acceptance Commitment Therapy (ACT) combined with motivation enhancement and a special app called ChillTime to see if these tools can help reduce methamphetamine use. This program is designed to be flexible, allowing participants to take part from the comfort of their homes, although there is also an option for in-person meetings if needed.
To be eligible for this trial, participants must be over 18 years old, identify as female, woman, or non-binary, and meet specific criteria for methamphetamine use disorder. They should be able to communicate in English and provide informed consent. However, individuals experiencing severe mental health issues, such as acute psychosis or intense suicidal thoughts, may not qualify due to safety concerns. Overall, participants can expect a supportive environment aimed at improving their health and well-being while using innovative methods to manage their substance use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meet SCID DSM-5 criteria for Methamphetamine Use Disorder
- • Over the age of 18
- • Female, woman, or non-binary and comfortable participating in women's group
- • Capacity to provide informed consent
- • Adequate English language abilities
- Exclusion Criteria:
- • Experiencing acute or unmedicated psychosis that would reasonably prevent them from engaging in and/or benefiting from the intervention
- • Experiencing acute and severe suicidal ideation such that institutionalization and supervised care is warranted
- • Experiencing severe cognitive deficits that would reasonably prevent them from consenting, engaging in, and/or benefiting from the intervention
About Centre For Addiction And Mental Health
The Centre for Addiction and Mental Health (CAMH) is Canada’s leading mental health and addiction teaching hospital, dedicated to advancing research, clinical care, and education in the field of mental health. With a commitment to improving the lives of individuals affected by mental illness and addiction, CAMH conducts innovative clinical trials aimed at developing and evaluating new treatment approaches. The institution fosters a collaborative environment that brings together researchers, clinicians, and community partners to translate scientific findings into effective interventions, ensuring the highest standards of care and support for patients. Through its robust research initiatives, CAMH strives to enhance understanding of mental health disorders and promote evidence-based practices in the treatment of addiction and mental health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Bernard Le Foll, MD
Principal Investigator
Centre for Addiction and Mental Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials